Our goal: Increase patient engagement in research and improve research processes and develop policies that will better support efficient development and approval of new therapies.
FasterCures releases workshop report on value and coverage
"Value and Coverage: How reimbursement decisions impact innovations needed to improve health" articulates findings from a workshop convened on the topic and key actionable recommendations for patient-driven organizations to consider. In this report, FasterCures notes that when it comes to the issue of value and coverage for medical innovations, the medical research community is in search of a better understanding of the evidentiary standards that payers consider when reimbursing treatment and care. The report states that establishing safety and efficacy is no longer sufficient when developing a new therapy; innovators must also prove value to patients, providers, and payers in order to generate a revenue stream that covers their R&D costs and provides adequate profits to fuel the next discovery's translation and commercialization. The report outlines a series of recommendations specifically for patient organizations to consider. Recommendations fall under three major themes: collaboration; leveraging data; and deploying smarter, better care.
FasterCures supports investment in NIH through United for Medical Research
FasterCures continues to support National Institutes of Health (NIH) appropriations through United for Medical Research (UMR), a consortium of patient, provider, and research organizations, as an active member and serving on the steering committee. Recent articles have brought attention to NIH funding, including an article in the Washington Post in which Carrie Wolinetz, president of UMR, said the proposed spending bill “won’t adequately reverse the damage done by last year’s budget sequester and ensure the nation’s biomedical research enterprise makes continued progress in lifesaving research and development.”
R&D Policy page offers resources about protecting federal investment in medical research
FasterCures' R&D Policy page includes letters, reports, and more that demonstrate how the federal investment in medical research saves lives, creates jobs, and maintains U.S. leadership in the global economy. The page also includes coverage of the federal funding impact on states and the federal investment in innovation.
Blog: The Future of Medicine
We already have the technology to monitor dozens of body parameters in real time, and much more is on the way, writes Bernard Munos, FasterCures senior fellow, in a blog post. The problem is that today all these data end up in different places, in different formats and are hardly exploitable, he says. But that could easily change.
Our goal: Stimulate innovative collaborations across all sectors - academia, government, industry, investors, and nonprofits - to speed up the time it takes to get new therapies from the lab to patients.
Rock Health’s top 50 digital health entrepreneurs
Business accelerator and health IT seed fund Rock Health recently named the top 50 people with the most significant impact in digital health technology in 2013, a list that features FasterCures Executive Director Margaret Anderson. The list also included startup co-founders and CEOs, venture investors, and nonprofit and university officials. According to the article, "These are the people who inspire and motivate us by working to change the world for the healthier."
Anderson speaks about ‘Digital Health Manifesto’
At the Consumer Electronics Show in Las Vegas on Jan. 9, Margaret Anderson joined a panel of healthcare leaders to identify and resolve barriers that impede marketplace success in order to optimize the health of the nation. The panel was moderated by Reed Tuckson of Tuckson Health Connections and included speakers from New Atlantic Ventures, Qualcomm Life, "The Doctors"/MD LIVE, Audax Health, and Kaiser Permanente.
Our goal: Facilitate greater access to and more strategic allocation of capital to support results-driven medical research.
Highlighting novel R&D funding models
Be sure to check out case studies on 10 novel approaches to financing early-stage drug development, including an orphan disease drug development accelerator, a precompetitive alliance to create shared cancer model platforms, a biotechnology company that experimented with crowdfunding, and more.